HighTower Advisors’s Tourmaline Bio TRML Stock Holding History

HighTower Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-53,418	Closed	-$2.55M	–	3963
2025 Q3	$2.55M	Buy	53,418 +11,073	+26%	+$307K	﹤0.01%	1496
2025 Q2	$677K	Sell	42,345 -11,073	-21%	-$179K	﹤0.01%	2286
2025 Q1	$812K	Hold	53,418	–	–	﹤0.01%	2099
2024 Q4	$1.08M	Hold	53,418	–	–	﹤0.01%	1901
2024 Q3	$1.37M	Hold	53,418	–	–	﹤0.01%	1731
2024 Q2	$688K	Hold	53,418	–	–	﹤0.01%	2093
2024 Q1	$1.22M	Hold	53,418	–	–	﹤0.01%	1695
2023 Q4	$1.4M	Buy	+53,418	New	+$1.07M	﹤0.01%	1659
2023 Q3	–	Sell	-44,836	Closed	-$1.36M	–	3751
2023 Q2	$1.36M	Buy	+44,836	New	+$1.14M	﹤0.01%	1572

HighTower Advisors's TRML Position: Q4 2025 in Review

HighTower Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 53,418 shares — an estimated $2.55M sold.

HighTower Advisors first reported a position in TRML in Q2 2023 and held it in 9 quarters. The position peaked at $2.55M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

HighTower Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 53,418 Tourmaline Bio shares in Q4 2025, an estimated $2.55M.
HighTower Advisors first reported a position in Tourmaline Bio in Q2 2023 and held it in 9 quarters.
HighTower Advisors's Tourmaline Bio position peaked at $2.55M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.